Novo Nordisk warns of counterfeit Ozempic injections

Novo Nordisk (NVO) said it has become aware of several hundred units of Ozempic injection outside the Novo Nordisk authorized supply chain in the U.S. The US Food and Drug Administration has also updated its website with information about these counterfeit versions of Ozempic. “As the investigation continues, further analyses, including extensive visual examination and chemical testing of the seized, counterfeit product is underway. Accordingly, neither Novo Nordisk nor FDA can confirm the contents or quality of the counterfeit product, which may present a safety risk for patients who use the counterfeit product,” the company said in a statement.